Latest news and upcoming events
LAVA Therapeutics Presents Preclinical Data on its GammabodyTM T Cell Engager Platform at the 21st Annual PepTalk Conference
New non-human primate data support the safety and tolerability profile of LAVA’s lead solid tumor GammabodyTM programs
Lava Therapeutics to present corporate overview at 40TH annual J.P. Morgan healthcare conference
Stephen Hurlywill present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12
NorthSea Therapeutics Completes US$80 Million Series C Fundraising to Advance Clinical Programs in Metabolic Disorders
The financing round was co-led by Ysios Capital and Forbion Growth and joined by new investors; a large managed care organization, and Hercules Capital, Inc.
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001
Major corporate milestone achieved as VarmX transitions into a clinical-stage company
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer
Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors
Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space.
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
Carmel M. Lynch, PhD, as Chief Development Officer (CDO) and Pernille Høyrup Hemmingsen, PhD, as Chief Technology Officer (CTO). Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).
Dutch med-tech innovator Xeltis lands €15 million European financing from EIB
Xeltis will use the funding to accelerate the clinical programmes of three restorative devices that can substantially impact cardiovascular
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology
Purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to EUR 170 million and progressive commercial milestones.
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases
Today’s acquisition marks a pivotal moment for Kala and a meaningful acceleration toward our goal of strengthening Kala’s pipeline for the treatment of front and back of the eye diseases,
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.